By September 30, 2026, Huawei was reportedly rolling out its Diabetes Risk Study to HUAWEI WATCH GT 7 and HUAWEI WATCH GT 7 Pro owners in parts of Europe, the Middle East and Africa. The feature estimates hyperglycemia risk; it does not measure blood glucose.
Where the reported rollout reached
The rollout was described as underway in parts of Europe, the Middle East and Africa by September 30. The report named both the HUAWEI WATCH GT 7 and HUAWEI WATCH GT 7 Pro.
How the Watch GT 7 study is described
The reported assessment uses optical PPG sensors to collect pulse-wave data over 3–14 days. PPG is a method that uses light to track pulse-related changes. The reported account says the assessment also considers age, sex, height and weight. A GT 7 Pro segment describes exercise and sleep data as additional inputs.
For the GT 7 Pro, the described results fall into three categories: low, medium or high risk.
A risk category is not a glucose result
The Diabetes Risk Study estimates risk; it does not provide a blood-glucose value or diagnose diabetes. The result is not intended to guide changes to medical treatment.
Huawei’s separate blood-sugar device project
At a Peking University keynote, Huawei Consumer Business Group CEO He Gang was reportedly describing four years of development work on non-invasive blood-sugar technology and a dedicated testing device under development.
